Drug marketing gone more mad

I’m talking about desvenlafaxine or to give it its bright shiny new marketing name – Pristiq. CL Psych writes:

“Pristiq is Wyeth’s attempt to cover up for their bestseller Effexor coming off patent in the near future. Coverup? Considering that desvenlafaxine is a clear knockoff of Effexor (venlafaxine), yes, I’m sticking with that descriptor. Why do research to develop an innovative medication when you can just sell one that is quite highly similar to the one that is already a sales blockbuster?

The idea is not new – make a drug that very closely resembles your existing product, then get it FDA-approved slightly before the old one goes off patent. Lexapro-Celexa, Invega-Risperdal, and now Effexor-Pristiq. The new drug offers no advantage over the drug that is about to go generic…”

How do they get away with this kind of thing?

2 Responses to “Drug marketing gone more mad”

  1. RB Says:

    They get away with this kind of thing because of the ching ching … £££££££££££££££££$$$$$$$$$$$$$$$$$$

    Big Pharma is up there with the arms dealers and the tobacco companies…

    Corporate Crime seems to be above the law…

  2. RB Says:

    They get away with this kind of thing because of the ching ching … £££££££££££££££££$$$$$$$$$$$$$$$$$$

    Big Pharma is up there with the arms dealers and the tobacco companies…

    Corporate Crime seems to be above the law…


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: